Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time

NCT00292552 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00292552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00292552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
December 31, 2005
Completion date
February 28, 2010
Enrollment
2,747 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary disease, chronic obstructive